# Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

> **NCT01845584** · PHASE2 · COMPLETED · sponsor: **Nihon Pharmaceutical Co., Ltd** · enrollment: 7 (actual)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **DRUG:** NPB-01

## Key facts

- **NCT ID:** NCT01845584
- **Lead sponsor:** Nihon Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01845584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01845584, "Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01845584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*